ENTERA BIO LTD. Adjustments For Decrease Increase In Trade Account Receivable
ENTERA BIO LTD. (ENTX) reported Adjustments For Decrease Increase In Trade Account Receivable of $139.00 thousand for the 6-month period ending 2021-06-30, per its 6-K filed 2021-08-16.
Discontinued › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable · last filed 2021-08-16
| Period end | Adjustments For Decrease Increase In Trade Account Receivable 6 month | Adjustments For Decrease Increase In Trade Account Receivable 12 month |
|---|---|---|
| 2021-06-30 | $139.00K 6-K · filed 2021-08-16 | |
| 2020-12-31 | $23.00K 20-F · filed 2021-03-18 | |
| 2020-06-30 | $278.00K 6-K · filed 2021-08-16 | |
| 2019-12-31 | $447.00K 20-F · filed 2021-03-18 | |
| 2019-06-30 | $725.00K 6-K · filed 2020-08-20 | |
| 2018-12-31 | -$725.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |